Targeted liposomal drug delivery in cancer

Current Pharmaceutical Design

Volumn 10, Issue 24, 2004, Pages 2981-2989

  Medina, Oula Penate ^a   Zhu, Ying ^a   Kairamo, Kalevi ^b  

^a Cancer Targeting Technologies Oy   (Finland)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cancer chemotherapy; Cytotoxic compounds; Liposomes; Monoclonal antibodies; Phage display peptides; Pharmacodynamics; Pharmacokinetics; Positron emission tomography; Radionuclide imaging; Tumor targeting

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ACICLOVIR; ALPHA TOCOPHEROL; AMIKACIN; AMPHOTERICIN B LIPID COMPLEX; ANNAMYCIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CAMPTOTHECIN; CIPROFLOXACIN; CISPLATIN; DAUNORUBICIN; DOXORUBICIN; DRUG VEHICLE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL DERIVATIVE; GLUCURONIC ACID; IMMUNOLIPOSOME; LIPOFECTAMINE; LIPOFECTIN; LIPOSOME; MACROGOL; PACLITAXEL; POLYMYXIN B; RADIOACTIVE MATERIAL; RETINOID; RIBOZYME; UNINDEXED DRUG; VINCRISTINE;

BIODEGRADABILITY; BREAST CANCER; CATARACT; CLINICAL TRIAL; COLON CANCER; COVALENT BOND; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TRANSPORT; ENCAPSULATION; GROWTH INHIBITION; HEART DISEASE; HUMAN; HYDRATION; HYDROPHILICITY; HYDROPHOBICITY; IN VIVO STUDY; KAPOSI SARCOMA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; SENDAI VIRUS; TARGET ORGAN; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 4544230514     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383467     Document Type: Review

References (120)

1. Gregoriadis G, ed. Liposome Technology, 2nd ed., CRC Press, Boca Raton, 1992.
2. Rolland A, ed. Pharmaceutical Particulate Carriers: Therapeutic applications, Marcel-Dekker, New York, 1993.
3. Lasic DD, ed. Liposomes: from physics to applications, Elsevier, Amsterdam, 1993.
4. Kreuter J, ed. Coloidal drug delivery systems, Marcel Dekker, New York. 1994.
5. Lasic DD, Martin F, eds. Stealth liposomes, CRC Press, Boca Raton. 1995.
6. Woodle MC, Storm G, eds. Long circulating liposomes: old drugs, new therapeutics, Springer, Berlin, 1998.
7. Oku N, Namba Y, Takeda A, Okada S. Tumor imaging with technetium-99m-DTPA encapsulated in RES-avoiding liposomes. Nucl Med Biol 1993; 20: 407-412.
8. Allen TM. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 1998; 56: 747-756.
9. Jovcic G, Bugarski D, Kataranovski M, Stojanovic N, Petakov M, Mejovic L, et al. The in vivo effect of liposomes on hematopoiesis. Drug Develop. Industrial Pharm 1999; 25: 517-521.
10. Bradley AJ, Brooks DE, Norris-Jones R, Devine DV. C1q binding to liposomes is surface charge dependent and is inhibited by peptides consisting of residues 14-26 of the human C1qA chain in a sequence independent manner. Biochim Biophys Acta 1999; 1418: 19-30.
11. Chonn A, Semple SC, Cullis PR. Separation of large unilamellar liposomes from blood components by a spin column proceduce: towards identifying plasma proteins which mediate liposome clearance in vivo. Biochim Biophys Acta 1991; 1070: 215-222
12. Funato K, Yoda R, Kiwada H. Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma. Biochim Biophys Acta 1992; 1103: 198-204.
13. Liu S, Ishida T, Kiwada H. Characterization of bovine serum factor triggering the lysis of liposomes via complement activation. Biol Pharm Bull 1998; 21: 390-397.
14. Huong TM, Harashima H, Kiwada H. In vivo studies on the role of complement in the clearance of liposomes in rats and guinea pigs. Biol Pharm Bull 1999; 22: 515-520.
15. Szebeni J. The interaction of liposomes with the complement system. Criti Rev Therapeu Drug Carrier Syst 1998; 15: 57-88.
16. Senior J, Crawley JCW, Gregoriadis G. Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection. J Biol Chem 1985; 839: 1-8.
17. Harashima H, Sakata K, Funato K, Kiwada H. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res 1994; 11: 402-406.
18. Oku N, Tokudome Y, Namba Y, Saito N, Endo M, Hasagawa Y, et al. Effect of serum protein binding on real-time trafficking of liposomes with different charges analyzed by positron emission tomography. Biochim Biophy Acta 1996; 1280: 149-154.
19. Gabizon A, Goren D, Cohen R, Barenholz Y. Development of liposomal anthracyclines: from basics to clinical applications. J. Controlled Release 1998; 53: 275-279.
20. Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, Shezen E, et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 1999; 86: 72-78.
21. Valero V, Buzdar AU, Theriault RL, Azarnia N, Fonseca GA, Willey J, et al. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide and flourouracil as first-line therapy in patients with metastatic breast cancer, J Clin Oncol 1999; 17: 1425-1434.
22. Krishna R, Mayer LD. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res 1997; 57: 5246-5253.
23. Oku N, Doi K, Namba Y, Okada S. Therapeutic effect Of adriamycin encapsulated in long-circulating liposomes on Meth-A-sarcoma-bearing mice. Int J Cancer 1994; 58: 415-419.
24. Zocchetti M, Boiardi A, Silvani A, Parisi I, Piccolrovazzi S, D'Incalci M. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin. Cancer Chemother Pharmacol 1999; 44: 173-176.
25. Verdonck LF, Lokhorst HM, Roovers DJ, van Heugten HG. Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: implications for liposome-encapsulated daunorubicin. Leukemia Res 1998; 22: 249-256.
26. Zou Y, Priebe W, Stephens LC, Perez-Soler R. Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity. Clin Cancer Res 1995; 1: 1369-1374.
27. Perez-Soler R, Shin DM, Siddik ZH, Murphy WK, Huber M, Lee SJ, et al. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Clin Cancer Res 1997, 3: 373-379.
28. Embree L, Gelmon K, Tolcher A, Hudon N, Heggie J, Dedhar C, et al. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol 1998 41: 347-352.
29. Tokudome Y, Oku N, Doi K, Namba Y, Okada S. Antitumor activity of vincristine encapsulated in glucuronide-modified long-circulating liposomes in mice bearing Meth A sarcoma. Biochim Biophys Acta 1996; 1279: 70-74.
30. Scialli AR, Waterhouse TB, Desesso JM, Rahman A, Goeringer GC. Protective effect of liposome encapsulation on paclitaxel developmental toxicity in the rat. Teratology 1997; 56: 305-310.
31. Cabanes A, Briggs KE, Gokhale PC, Treat JA, Rahman A. Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int J Oncol 1998; 12: 1035-1040.
32. Sadzuka Y, Hirotsu S, Hirota S. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11. Cancer Lett 1998; 127: 99-106.
33. Lundberg BB. Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions. Anti-Cancer Drug Design 1998; 13: 453-461.
34. van Borssum Waalkes M, Goris H, Dontje BH, Schwendener RA, Scherphof G, Nijhof W. Toxicity of liposomal 3′-5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine in mice. Anti-Cancer Drug Design 1998; 13: 291-305.
35. Mayer LD, Tai LC, Bally MB, Mitilenes GN, Ginsberg RS, Collis PR. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta 1990; 1025: 143-151.
36. Cortesi R, Gui V, Gambari R, Nastruzzi C. In vitro effect on human leukemic K562 cells of co-administration of liposome-associated retinoids and cytosine arabinoside (Ara-C). Am J Hematol 1999; 62: 33-43.
37. Lamproglou I, Magdelenat H, Boisserie G, Baillet F, Mayo W, Fessi H, et al. An experimental model of acute encephalopathy after total body irradiation in the rat: effect of liposome-entrapped Cu/Zn superoxide dismutase. Int J Radiation Oncol Biol Physics 1998; 42: 179-184.
38. Kimura T, Kurosawa H, Goto H, Kora S, Ogata Y, Amano Y. Oxygen carrying capacity and oxygen supply rate of artificial oxygen carrier, Neo Red Cell (NRC). Artificial Cells Blood Substitutes Immobilization Biotechnol 1998; 26: 455-464.
39. van der Veen AH, Eggermont AM, Seynhaeve AL, van Tiel, ten Hagen TL. Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-alpha in soft tissue sarcoma bearing rats. Int J Cancer 1998; 77: 901-906.
40. Moriya H, Maitani Y, Shimoda N, Takayama K, Nagai T. Pharmacokinetic and pharmacological profiles of free and liposomal recombinant human erythropoietin after intravenous and subcutaneous administrations in rats. Pharmaceut Res 1997; 14: 1621-1628.
41. van Slooten ML, Kircheis R, Koppenhagen FJ, Wagner E, Storm G. Liposomes as cytokine-supplement in tumor cell-based vaccines. Int J Pharmaceut 1999; 183: 33-36.
42. Rogers JA, Anderson KE. The potential of liposomes in oral drug delivery. Critical Reviews in Therapeutic Drug Carrier Syst 1998; 15: 421-480.
43. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987-993.
44. Iwanaga K, Ono S, Narioka K, Kakemi M, Morimoto K, Yamasita S, et al. Application of surface-coated liposomes for oral delivery of peptide: effects of coating the liposome's surface on the GI transit of insulin. J Pharm Sci 1999; 88: 248-252.
45. Wong JP, Yang H, Nagata L, Kende M, Levy H, Schnell G, et al. Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC. Vaccine, 1999; 17: 1788-1795.
46. Fresta M, Panico AM, Bucolo C, Giannavola C, Puglisi G. Characterization and in vivo ocular absorption of liposome-encapsulated acyclovir. J Pharm Pharmacol 1999; 51: 565-576.
47. Ohta Y, Torii H, Yamasaki T, Niwa T, Majima Y, Ishiguro I. Preventive action of vitamin E-containing liposomes on cataractogenesis in young adult rats fed a 25% galactose diet. J. Ocular Pharmacol Therapeut 1997; 13: 537-550.
48. Trafny EA, Antos-Bielska M, Grzybowski J. Antibacterial activity or liposome-encapsulated antibiotics against Pseudomonas aeruginosa attached to the matrix of human dermis. J Microencap 1999; 16: 419-429.
49. Knight V, Koshkina NV, Waldrep JC, Giovanella BC, Gilbert BE. Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol 1999; 44: 177-186.
50. Koshkina NV, Gilbert BE, Waldrep JC, Seyshev A, Knight V. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother Pharmacol 1999; 44: 187-192.
51. Yaksh TL, Provencher JC, Rathbun ML, Kohn FR. Pharmacokinetics and efficacy of epidurally delivered sustained-release encapsulated morphine in dogs. Anesthesiology 1999; 90: 1402-1412.
52. Gao X, Huang L. Cationic liposome-mediated gene transfer. Gene Ther 1995; 2: 710-22.
53. Almofti MR, Harashima H, Shinohara Y, Almofti A, Baba Y, Kiwada H. Cationic liposome-mediated gene delivery: biophysical study and mechanism of internalization. Arch Biochem Biophys 2003; 410: 246-53.
54. Barron LG, Gagne L, Szoka FC Jr. Cationic lipids are essential for gene delivery mediated by intravenous administration of lipoplexes. Human Gene Therapy 1999; 10: 1683-94.
55. Zelphati O, Nguyen C, Ferrari M, Felgner J, Tsai Y, Felgner PL, Stable and monodisperse lipoplex formulations for gene delivery. Gene Therapy 1998; 5: 1272-1782.
56. Okamoto S, Watanabe Y, Takakura Y, Hashida M, Cationic liposome-mediated efficient induction of type I interferons by a low dose of poly I:poly C in mouse cell lines. J Biochem 1998; 124: 697-701,
57. Mahato RI, Anwer K, Tagliaferri F, Meaney C, Leonard P, Wadhwa MS, et al. Biodistribution and gene expression of lipid/plasmid complexes after systemic administration. Human Gene Therapy 1998; 9: 2083-99.
58. Obika S, Yu W, Shimoyama A, Uneda T, Minami T, Miyashita K, et al. Properties of cationic liposomes composed of cationic lipid YKS-220 having an ester linkage: adequate stability, high transfection efficiency, and low cytotoxicity. Biological & Pharmaceutical Bull 1999; 22: 187-90.
59. Ryhanen SJ, Saily MJ, Paukku T, Borocci S, Mancini G, Holopainen JM, et al. Surface charge density determines the efficiency of cationic gemini surfactant based lipofection. Biophys J 2003; 84:578-87.
60. Nakanishi M, Mizuguchi H, Ashihara K, Senda T, Eguchi A, Watabe A, et al. Gene delivery systems using the Sendai virus. Mol Membr Biol 1999; 16: 123-127.
61. Ozkan I, Shino K, Nakamura N, Natsuume T, Matsumoto N, Horibe S, et al. Direct in vivo gene transter to healing rat patellar ligament by intra-arterial delivery of haemagglutinating virus of Japan liposomes. Eur J Clin Invest 1999; 29: 63-7.
62. Kaneda Y. Development of a novel fusogenic viral liposome system (HVJ-liposomes) and its applications to the treatment of acquired diseases. Mol Membr Biol 1999; 16: 119-22.
63. Maurer N, Mori A, Palmer L, Monck MA, Mok KW, Mui B, et al. Lipid-based systems for the intracellular delivery of genetic drugs. Mol Membr Biol 1999; 16: 129-40.
64. Oku N. Anticancer therapy using glucuronate modified long-circulating liposomes Adv Drug Delivery Rev 1999; 40: 63-73.
65. Allen TM, Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett 1987; 223: 42-6.
66. Oku N, Namba Y, Okada S. Tumor accumulation of novel RES-avoiding liposomes. Biochim Biophys Acta 1992; 1126: 255-60.
67. Namba Y, Oku N, Ito F, Sakakibara T, Okada S. Liposomal modification with uronate, which endows liposomes with long circulation in vivo, reduces the uptake of liposomes by J774 cells in vitro. Life Sci 1992; 50: 1773-1779.
68. Allen TM, Hansen C, Martin F, Redeman C, Yau-Yong A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991; 1066: 29-36.
69. Moribe K, Maruyama K, Iwatsuru M, Estimation of surface state of poly(ethylene glycol)-coated lipsomes using an aqueous two-phase partitioning technique. Chem Pharm Bull 1997; 45: 1683-7.
70. Ishiwata H, Sato SB, Kobayashi S, Oku M, Vertut-Doi A, Miyajima K. Poly(ethylene glycol) derivative of cholesterol reduces binding step of liposome uptake by murine macrophage-like cell line J774 and human hepatoma cell line HepG2. Chem. Pharm Bull 1998; 46: 1907-13.
71. Bradley AJ, Devine DV, Ansell SM, Janzen J, Brooks DE. Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids. Arch Biochem Biophys 1998; 357: 185-94.
72. Tseng YL, Hong RL, Tao MH, Chang FH. Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int J Cancer 1999; 80: 723-30.
73. Maeda H, Seymour LW, Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate Chem 1992; 3: 351-62.
74. Oku N, Namba Y. Long-circulating liposomes Crit. Rev. Ther. Drug Carrier Syst 1994; 11: 231-70.
75. Oku N, Namba Y, Takeda A, Okada S. Tumor imaging with technetium-99m-DTPA encapsulated in RES-avoiding liposomes Nucl Med Biol 1993; 20: 407-12.
76. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model, Clin Cancer Res 1998; 4: 1567-71.
77. Sadzuka Y, Hirota S. Does tile amount of an antitumor agent entrapped in liposomes influence its tissue distribution and cell uptake? Cancer Lett 1998; 131: 163-70.
78. Vaage J, Donovan D, Wipff E, Abra R, Colbern G, Uster P, et al. Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated Stealth liposomes. Int J Cancer 1999; 80: 134-7.
79. Working PK, Newman MS, Sullivan T, Brunner M, Podell M, Sahenk Z, et al. Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys. Toxicol Sci 1998; 46: 155-65.
80. Thamm DH, Vail DM. Preclinical evaluation of a sterically stabilized liposome-encapsulated cisplatin in clinically normal cats. American Journal of Veterinary Res 1998; 59: 286-9.
81. Oku N, Tokudome Y, Tsukada, H, Okada S. Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography. Biochim Biophys Acta 1995; 1238: 86-90.
82. Fidler I. The biology of human cancer metastases. Acta Oncol 1991; 30: 668-75.
83. Dieter P, Ambs P, Fitzke E, Schwende H. Lipopolysaccharide and liposome-encapsulated MTP-PE-induced cytotoxicity and release of eicosanoids, tumor necrosis factor- alpha and nitric oxide in liver macrophages. Adv Exp Med Biol 1997; 407: 485-90.
84. Worth LL, Jia SF,.An T, Kleinerman ES. ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity. Cancer Immunol Immunother 1999; 48: 312-20.
85. ten Hagen TL, van Vianen W, Savelkoul HE, Heremans H, Buurmam WA, Bakker-Woudenberg IA. Involvement of T cells in enhanced resistance to Klebsiella pneumoniae septicemia in mice treated with liposome-encapsulated muramyl tripeptide phosphatidylethanolamine or gamma interferon. Infect Immunity 1998; 66: 1962-7.
86. Bakker J, Sanders A, Van Rooijen N. Effects of liposome-encapsulated drugs on macrophages: comparative activity of the diamidine 4′,6-diamidino-2-phenylindole and the phenanthridinium salts ethidium bromide and propidium iodide. Biochim Biophy Acta 1998; 1373: 93-100.
87. Hoch JR, Stark VK, van Rooijen N, Kim JL, Nutt MP, Warner TF. Macrophage depletion alters vein graft intimal hyperplasia. Surgery 1999; 126: 428-37.
88. Palermo MS, Alves Rosa MF, Van Rooijen N, Isturiz MA. Depletion of liver and splenic macrophages reduces tile lethality of Shiga toxin-2 in a mouse model. Clin Exp Immunol 1999; 116: 462-7.
89. Storm, Crommelin, liposomes: Quo vadis? Pharm Sci & Tech Today 1998; 1: 19-31.
90. Dagar S, Sekosan M, Lee BS, Rubinstein I, Onyuksel H. VIP receptors as molecular targets of breast cancer: implications for targeted imaging and drug delivery. Journal of Controlled Release 2001; 74(1-3): 129-34.
91. Medina OP, Söderlund T, Laakkonen LJ, Tuominen EKJ, Koivunen E, Kinnunen PKJ. Binding of Novel Peptide Inhibitors of Type IV Collagenases to Phospholipid Membranes and Use in Liposome Targeting to Tumor Cells in Vitro. Cancer Res 2001; 61: 3978-85.
92. Pegram MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Seminars Oncol 2002; 29(Suppl. 11): 29-37.
93. Chang SS, Bander NH, Heston WD. Monoclonal antibodies: will they become all integral part of the evaluation and treatment of prostate cancer - focus on prostate-specific membrane antigen? Curr Opinion Urol 1999; 9: 391-95.
94. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996; 380: 364-66,
95. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-80.
96. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 2002; 8: 751-55.
97. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, et al. Steps toward mapping the human vasculature by phage display. Nat Med 2002; 8: 121-27.
98. Nguyen M, Arkell J, Jackson CJ. Human endothelial gelatinases and angiogenesis. Int J. Biochem. Cell Biol 2001; 33: 960-70.
99. Swallow CJ, Murray MP, Guillem JG. Metastatic colorectal cancer cells induce matrix metalloproteinase release by human monocytes. Clin. Exp. Metastasis 1996; 14: 311.
100. Saad S, Gottlieb DJ, Bradstock KF, Overall CM, Bendall LJ. Cancer cell-associated fibronectin induces release of matrix metalloproteinase-2 from normal fibroblasts. Cancer Res 2002; 62: 283-89.
101. Koivunen E, Arap W, Valtanen E, Rainisalo A, Medina OP, Heikkilä P, et al. Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol 1999; 17: 768-74.
102. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 2001; 7: 743-48.
103. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-74.
104. Pozzi A, LeVine WF, Gardner HA. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 2002; 21: 272-82.
105. Webb MS, Saxon D, Wong FM, Lim HJ, Wang Z, Bally MB, et al. Biochim Biophy Acta 1998; 1372: 272-82.
106. Colbern GT, Dykes DJ, Engbers C, Musterer R, Hiller A, Pegg E, et al. Clin Cancer Res 1998; 4: 3077-82.
107. Oku N, Tokudome Y, Tsukada H, Kosugi T, Namba Y, Okada S. Biopharm Drug Dispositon 1996; 17: 435-41.
108. 99mTc Labeling of Pegylated Liposomal Doxorubicin (Doxil(R)) for Pharmacokinetic and Non-invasive Imaging Studies. J Pharmacol Exp Ther 2003.
109. Bao A, Goins B, Klipper R, Negrete G, Mahindaratne M, Phillips WT. A novel liposome radiolabeling method using 99mTc-" SNS/S" complexes: in vitro and in vivo evaluation. J Pharm Sci 2003; 92: 1893-904.
110. Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 2002; 10: 539-48
111. Suresh M, Cao Y. A simple and efficient method for radiolabeling of preformed liposomes. J Pharm Pharm Sci 1998; 1: 31-7.
112. Phillips WT, Rudolph AS, Goins B, Klipper R. Biodistribution studies of liposome encapsulated hemoglobin (LEH) studied with a newly developed 99m-technetium liposome label. Biomater Artif Cells Immobilization Biotechnol 1992; 20: 757-60.
113. Belhaj-Tayeb H, Briane D, Vergote J, Kothan S, Leger G, Bendada SE, et al. In vitro and in vivo study of (99m)Tc-MIBI encapsulated in PEG-liposomes: a promising radiotracer for tumour imaging. Eur J Nucl Med Mol Imaging 2003; 30: 502-9.
114. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003; 42:419-36
115. Marina NM, Cochrane D, Harney E, Zomorodi K, Blaney S, Winick N, et al. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Clin Cancer Res 2002; 8: 413-8
116. Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, van Rooijen N, et al. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. Journal of Pharmacology & Experimental Therapeutics 2001; 298(2): 607-12.
117. Laverman P, Brouwers AH, Dams ET, Oyen WJ, Storm G, van Rooijen N, et al. Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose. Journal of Pharmacology & Experimental Therapeutics 2000; 293(3): 996-1001.
118. Maesaki S. Drug delivery system of anti-fungal and parasitic agents. Curr Pharm Design 2002; 8(6): 433-40.
119. Moribe K, Maruyama K. Pharmaceutical design of the liposomal antimicrobial agents for infectious disease. Curr Pharm Design 2002; 8(6): 441-54.
120. Yanagihara K. Design of anti-bacterial drug and anti-mycobacterial drug for drug delivery system. Curr Pharm Design 2002; 8(6): 475-82